Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582074 · ClinicalTrials.gov registry record
The Ultrasound Study of Tamoxifen
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 247
- Enrollment target
NCT01582074: Completed study, sponsored by National Cancer Institute (NCI).
NCT01582074 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 247 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582074 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 247 participants
- Enrollment target
Study Summary
Background: \- Studies have shown that changes in breast density (the amount of white area on a woman's mammogram) may be related to changes in breast cancer risk. Currently, there is no ideal way to measure breast density repeatedly over time. Researchers want to test whether ultrasound tomography scans can show changes in breast density. To examine these changes, healthy volunteers with no history of breast cancer and women who are taking tamoxifen will have ultrasound tomography scans. Objectives: \- To test whether ultrasound tomography scans can show changes in breast density related to tamoxifen exposure. Eligibility: \- Women between 30 and 70 years of age who are (a) taking tamoxifen or (b) healthy volunteers who have never had breast cancer. Design: * All participants will have a screening visit. Healthy volunteers will have one additional study visit; women taking tamoxifen will have three additional study visits. * All participants will be screened with a physical exam and medical history. They will also give blood and saliva samples. This visit will also include an initial ultrasound tomography breast scan. * For the healthy volunteers: * At the study visit (12 months after the screening visit), participants will have a short interview and be weighed. They will also have an ultrasound tomography breast scan and provide a blood sample. * For the women taking tamoxifen: * At the second and third visits (1 to 3 months and 3 to 6 months after starting tamoxifen), participants will have a short interview. They will also be weighed and have an ultrasound tomography breast scan. * At the fourth visit (12 months after starting tamoxifen), participants will have a short interview, weight measurement, and the ultrasound tomography breast scan, and will also provide a blood sample. * All participants may be followed for up to 5 years after their final study visit.
Primary Outcome
Change in breast density
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2011-07-05 |
| Est. Completion | 2016-01-01 |
What the finished NCT01582074 record still lists
NCT01582074 is an observational study that tracks outcomes without assigning an intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01582074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01582074 about?
NCT01582074 is a clinical study titled "The Ultrasound Study of Tamoxifen". Background: \- Studies have shown that changes in breast density (the amount of white area on a woman's mammogram) may be related to changes in breast cancer risk. Currently, there is no ideal way to measure breast density repeatedly over time. Researchers want to test whether ultrasound tomography...
What is the current status of trial NCT01582074?
This trial is currently completed. The enrollment target is 247 participants. The study started on 2011-07-05. Estimated completion is 2016-01-01.
Who is sponsoring clinical trial NCT01582074?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI